Identification of a New Morpholine Scaffold as a P2Y12 Receptor Antagonist [PDF]
Molecules, 2016 The P2Y12 receptor is critical for platelet activation and is an attractive drug target for the prevention of atherothrombotic events. Despite the proven antithrombotic efficacy of P2Y12 inhibitors, these thienopyridine scaffolds are prodrugs that lack ...
Young Ha Ahn +6 more
doaj +7 more sources
P2Y12 receptor gene polymorphisms are associated with epilepsy. [PDF]
Purinergic Signal, 2023 AbstractThe basic research indicated that microglial P2Y12 receptors (P2Y12Rs) are involved in the pathophysiology of epilepsy through regulated microglial-neuronal interactions, aberrant neurogenesis, or immature neuronal projections. However, whether the clinic case of epilepsy would be associated with P2Y12 receptor gene polymorphisms is presented ...
Wang Q +12 more
europepmc +4 more sources
P2Y12 receptor as a new target for electroacupuncture relieving comorbidity of visceral pain and depression of inflammatory bowel disease [PDF]
Chinese Medicine, 2021 Background The P2Y12 receptor is a kind of purinoceptor that is engaged in platelet aggregation, and P2Y12 inhibitors have been used in clinical antithrombotic therapy. The P2Y12 receptor in microglia induces interleukin-1β (IL-1β) expression, which is a
Yanzhen Li +13 more
doaj +2 more sources
Early treatment with inhibitors of P2Y12 receptor in patients with ST-segment elevation myocardial infarction — 2023 ESC recommendations and scientific evidence. Is clinical evidence sufficient to suggest a move towards precision medicine? The ELECTRA-SIRIO 2 investigators’ viewpoint [PDF]
Cardiology JournalThe 2023 ESC guidelines changed previously recommended a strategy of early treatment in patients with STEMI. Pre-treatment with a P2Y12 receptor inhibitor may be considered in patients undergoing a primary PCI strategy (Class IIb, Level of evidence B ...
Jacek Kubica +31 more
doaj +2 more sources
The effect of P2Y12 receptor inhibitors on clinical outcomes in patients with acute coronary syndrome undergoing primary percutaneous intervention and receiving abciximab [PDF]
Cardiology JournalBACKGROUND: Our study compared the effect of P2Y12 receptor inhibitors in combination with abciximab on clinical outcomes in patients with acute coronary syndrome (ACS).
Onur Altınkaya +9 more
doaj +2 more sources
Real-time platelet P2Y12 receptor occupancy as a promising pharmacodynamics biomarker for bridging the gap between PK/PD of clopidogrel therapy [PDF]
Acta Pharmaceutica Sinica BClopidogrel effectively inhibits platelet aggregation in response to ADP by irreversibly binding to the platelet P2Y12 receptor through its active metabolite. However, the observed discrepancies between the pharmacokinetics (PK) and pharmacodynamics (PD)
Haipeng Li +5 more
doaj +2 more sources
Role and recent progress of P2Y12 receptor in cancer development. [PDF]
Purinergic SignalP2Y12 receptor (P2Y12R) is an adenosine-activated G protein-coupled receptor (GPCR) that plays a central role in platelet function, hemostasis, and thrombosis. P2Y12R activation can promote platelet aggregation and adhesion to cancer cells, promote tumor angiogenesis, and affect the tumor immune microenvironment (TIME) and tumor drug resistance, which ...
Xi Y, Min Z, Liu M, Lin X, Yuan ZH.
europepmc +4 more sources
Inhibiting P2Y12 receptor relieves LPS-induced inflammation and endothelial dysfunction [PDF]
Immunity, Inflammation and Disease, 2022 Xiuxia Han
exaly +2 more sources
Applied Sciences, 2021 The P2Y receptor family is a class of G protein-coupled receptors activated primarily by adenosine triphosphate (ATP), adenosine diphosphate (ADP), uridine triphosphate (UTP) and uridine diphosphate (UDP).
Lu Wang +6 more
doaj +1 more source
Distinct microglial response against Alzheimer's amyloid and tau pathologies characterized by P2Y12 receptor. [PDF]
Brain Communications, 2021 Hiroyasu Akatsu +2 more
exaly +2 more sources